Alector, Inc. (NASDAQ:ALEC – Free Report) – Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of Alector in a research note issued to investors on Thursday, February 27th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($2.02) for the year, up from their previous estimate of ($2.55). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share.
Alector (NASDAQ:ALEC – Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.59. The company had revenue of $54.24 million during the quarter, compared to analysts’ expectations of $20.41 million. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%.
Check Out Our Latest Stock Analysis on Alector
Alector Trading Up 3.2 %
NASDAQ ALEC opened at $1.46 on Monday. The business’s 50-day moving average price is $1.75 and its two-hundred day moving average price is $3.43. Alector has a 12 month low of $1.30 and a 12 month high of $7.10. The firm has a market capitalization of $144.17 million, a PE ratio of -0.86 and a beta of 0.61.
Hedge Funds Weigh In On Alector
A number of hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC purchased a new stake in Alector during the 4th quarter valued at $25,000. Tema Etfs LLC bought a new position in shares of Alector in the 4th quarter valued at about $27,000. Tower Research Capital LLC TRC lifted its holdings in shares of Alector by 71.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company’s stock valued at $28,000 after acquiring an additional 6,096 shares during the last quarter. Point72 DIFC Ltd bought a new stake in Alector in the third quarter worth about $29,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Alector in the third quarter worth about $40,000. 85.83% of the stock is currently owned by hedge funds and other institutional investors.
Alector Company Profile
Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
Read More
- Five stocks we like better than Alector
- What is the S&P 500 and How It is Distinct from Other Indexes
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Insider Trades May Not Tell You What You Think
- Tesla Stock: Finding a Bottom May Take Time
- Trading Stocks: RSI and Why it’s Useful
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.